CLL patients with Rai Stage 0 had significantly higher levels of IL-17A (median: 44.63 pg/ml) than those with Rai Stages I–II (median: 35.33 pg/ml) or III–IV (median: 15.23 pg/ml) (Figure 3A). Here, IL17A is linked to B-cell chronic lymphocytic leukemia.